Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M A, Plaizier"'
Autor:
G. J. Van Kamp, R. de Bree, Jan C. Roos, W. Den Hollander, M. A.B.D. Plaizier, G. B. Snow, G.A.M.S. (Guus) van Dongen, J. J. Quak
Publikováno v:
British Journal of Cancer, 75(7), 1049-1060. Nature Publishing Group
British Journal of Cancer
De Bree, R, Roos, J C, Plaizier, M A B D, Quak, J J, Van Kamp, G J, Den Hollander, W, Snow, G B & Van Dongen, G A M S 1997, ' Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients ', British Journal of Cancer, vol. 75, no. 7, pp. 1049-1060 . https://doi.org/10.1038/bjc.1997.179
British Journal of Cancer
De Bree, R, Roos, J C, Plaizier, M A B D, Quak, J J, Van Kamp, G J, Den Hollander, W, Snow, G B & Van Dongen, G A M S 1997, ' Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients ', British Journal of Cancer, vol. 75, no. 7, pp. 1049-1060 . https://doi.org/10.1038/bjc.1997.179
Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that 99mTc-labelled murine monoclonal antibodies (MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In t
Autor:
I, van Zanten-Przybysz, C F, Molthoff, J C, Roos, M A, Plaizier, G W, Visser, R, Pijpers, P, Kenemans, R H, Verheijen
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(7)
We investigated the safety and pharmacokinetics of (131)I-labeled chimeric monoclonal antibody MOv18 ((131)I-c-MOv18 IgG) in patients with ovarian cancer and the estimated radiation dose to cancer-free organs and tumor.Three patients were injected in
Autor:
J C, Roos, M A, Plaizier, A, van Lingen, H J, Haisma, W, den Hollander, H J, Martens, J J, Nauta, R L, Dejager, G J, Teule, E, Boven
Publikováno v:
In vivo (Athens, Greece). 7(6A)
Sequential immunoscintigrams were used to describe the relative distribution and kinetics of 8 mg 131I-labeled human IgM monoclonal antibody 16.88 in 20 patients with colorectal cancer. The results show that the initial activity was higher and the cl